Edwards Lifesciences Corp. closed 24.63% below its 52-week high of $96.12, which the company reached on March 28th.
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brighton Jones LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the fourth quarter, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback